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Background: Worldwide, there were 650,000 multidrug-resistant tuberculosis (MDR-TB) cases in 2010, and in 2008
the World Health Organization estimated that 150,000 deaths occurred annually due to MDR-TB. Ethiopia is 15th
among the 27 MDR-TB high-burden countries. This study identifies factors associated with the occurrence of MDR-TB
in patients who underwent first-line TB treatment in Addis Ababa City.
Methods: A case control study was conducted at St. Peter Hospital and five health centers in Addis Ababa from 1
November 2011 to February 30, 2012. Cases were MDR-TB patients who were confirmed with culture and drug-
susceptibility testing and were in treatment at St. Peter Hospital during the study period. Controls were patients who
were on first-line anti-TB treatment and were registered as cured or having completed treatment in the period 9 April
2009– 28 February 2010, in five health centers of Addis Ababa City. Accordingly, 134 cases and an equal number of
controls were included in this study. A structured interview questionnaire was used to assess factors that could
potentially be associated with the occurrence of MDR-TB.
Results: Factors that were significantly associated with MDR-TB: drug side effects during first-line treatment (adjusted
odds ratio (AOR): 4.5, 95% CI; 1.9 - 10.5); treatment not directly observed by a health worker (AOR = 11.7, 95% CI; 4–34.3);
interruption of treatment of at least a day (AOR = 13.1, 95% CI 3.0-56.6); duration of treatment between 2 and 7 months
(AOR = 14.8, 95% CI 2.3-96.4); and retreatment with the Category II regimen (P = 0.000). In the current study, HIV
infection was not significantly associated with the occurrence of MDR-TB.
Conclusions: Patients who were not in strict DOTS programs and did not adhere to first-line TB treatment and patients
who experienced side effects during first-line treatment and Category II retreatment were at significantly increased risk
of developing MDR-TB. The DOTS program should, therefore, be strengthened to increase patient adherence. Drug-
susceptibility testing is also highly recommended for all Category I treatment regimen failures before those patients
begin the Category II regimen.
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Multidrug-resistant tuberculosis (MDR-TB) is a type of
TB that is resistant to at least the first line anti-TB
drugs, Rifampacin and Isoniazid. MDR-TB occurs either
when a person is infected with a resistant strain or when
improper treatment leads to drug selection of the resist-
ant strain [1]. When an individual who has no history of
first-line TB treatment develops MDR-TB, it is termed
primary. When insufficient treatment leads to selection
of spontaneously resistant strains (i.e., drug resistance is
acquired), the disease is termed secondary MDR-TB [2].
Worldwide, there were 650,000 MDR-TB cases in
2010, and in 2008 World Health Organization (WHO)
estimated that there were 150,000 deaths annually due
to MDR-TB [3]. Overall, the 27 high MDR-TB burden
countries accounted for 85% of all MDR-TB cases.
China, and India, was the top two countries accounting
50% MDR-TB cases [3]. A 2010 WHO report showed
that the number of MDR-TB cases is rising in Africa [1].
Ethiopia is 15th among the 27 MDR-TB high-burden
countries, with an estimated 5,200 cases occurring each
year [4].
The occurrence of MDR- TB is mainly attributable to
human error, although genetic factors are also believed
to contribute to a certain extent [5]. The principal
patient-related factor that predicts the occurrence of
MDR-TB is non-adherence to treatment [6]. The first-
line anti-TB drugs used in Ethiopia in 2009/2010 were
rifampicin (R), ethambutol (E), isoniazid (H), and pyra-
zinamide (Z) [7]. The category II treatment regimen
(S (ERHZ) for two months, ERHZ for one month and
E (RH) for five months three times a week), which
adds streptomycin to the category I regimen (ERHZ
for two months and RH for four months) has been
blamed for increasing the risk of developing MDR-TB
[8], despite the fact that patients have already been
exposed to most of the drugs.
The emergence of MDR-TB is a threat for the popula-
tions of resource-limited countries. In Ethiopia, the low
socioeconomic status of the people, high prevalence of
infectious diseases and limited access to well-equipped
health care facilities worsens the effect of MDR-TB. Fur-
thermore, poor treatment outcomes, longer treatment
time (about two years), higher treatment costs, and
many more complications make MDR-TB a more com-
plex disease than TB [1,9]. In 2010, less than 5% of new
and previously treated TB patients were tested for
MDR-TB because of limited availability of the test in
most developing countries [10]. For example in Ethiopia,
in 2010 the ratio of laboratories capable of performing
mycobacterial culture was 0.1 per 5 million populations
[10]. Similarly, the ratio of laboratories capable of run-
ning line probe assays (LPA) for rapid detection of
MDR-TB was 0.1 per 5 million populations [10]. At thetime of this study in Ethiopia, the LPA, or culture using
Lőwenstein-Jensen media (LJ), and drug-susceptibility
testing (DST) were provided only at the Ethiopian
Health Nutrition and Research Institute (EHNRI) in
Addis Ababa.
MDR-TB occurs mostly in relation to improper treat-
ment of drug-susceptible TB. In countries like Ethiopia
MDR-TB is becoming a challenge because of poor ad-
herence to treatment and an increase in the use of illegal
and unapproved treatment regimens for MDR-TB [9].
To make things worse, in these TB and MDR-TB high-
burden countries patients stay in their communities for
longer periods without being diagnosed or getting
proper treatment. Even after diagnosis, because there are
few diagnostic and treatment facilities and a lack of
trained health professionals and drugs, patients do not
start treatment immediately. This delay potentially al-
lows easy spread of the disease to a large number of in-
dividuals within a short time. The aim of this study is to
asses factors that determine the occurrence MDR-TB
among patients who had taken first line anti-TB treat-
ment in Addis Ababa City.
Methods
Study area and study design
This health institution–based case control study was
conducted between 1 November 2011 and 28 February
2012 in Addis Ababa, the capital city of Ethiopia. The
estimated population size of Addis Ababa is 2.74 million
and the male population constitutes 48% [11]. Adminis-
tratively, the city is divided into 10 sub-cities and further
classified into 99 kebeles (lowest government administra-
tive unit). The health institutions in the city includes 47
hospitals, 204 private higher clinics, 226 private mid-
level clinics (known as medium clinics), 143 private
lower clinics, and 37 government health centers [Addis
Ababa Health Bureau report].
Study setting
Cases were selected from St. Peter Hospital, one of the
two MDR-TB patient treatment centers in Addis Ababa,
and controls were selected from Addis Ketema Health
Center in Addis Ketema sub-city; Woreda 9 Health Cen-
ters in Kolfe Keranyo sub-city; Lideta Health Center in
Lideta sub-city; Kasanches Health Center in Kirkos sub-
city; and Woreda 19 and Nifas Silk Lafto health centers
in Nifas Silk Lafto sub-city.
Eligibility of study participants
MDR-TB patients diagnosed by LPA, or culture using LJ,
and DST at the EHNRI and who were being treated at
St. Peter Hospital during the study period were consid-
ered as cases. In Ethiopia a patient is a suspect for
MDR-TB if he/she is a symptomatic close contact of a
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from a known high-risk group such as health workers; a
case of treatment failure; a new TB patient who remains
smear positive after 2 months of treatment (for new
cases) and after 3 months of retreatment with first-line
treatment or retreatment (e.g., return after default, re-
lapse) [12]. The controls were patients who had com-
pleted first-line anti-TB treatment and were declared
cured or treatment completed using the WHO criteria
and adopted by FMOH of treatment outcomes [13] be-
tween 9 April 2009 and 28 February 2010. Additionally,
the controls were those with no clinical symptoms of TB
based on the WHO criteria.
Recruitment of study participants
During the study period there were 147 eligible con-
firmed MDR-TB cases at St. Peter Hospital, 134 of who
consented to participate in the study. These patients
were residents of Addis Ababa who had a history of tak-
ing their first course of first-line TB treatment and were
on MDR-TB treatment during the period of data collec-
tion. Prior to identification of the controls, five health fa-
cilities were identified based on the number of MDR-TB
cases that they referred to St. Peter Hospital. The same
number of controls was selected from each of these five
health facilities. The sampling frame comprised all pa-
tients who had completed first-line anti-TB treatment
and were registered as cured or treatment completed.
Following this, the required sample size of the control
group was selected using systematic random sampling.
When a selected patient declined to participate in the
study, the next person in the register was taken.
The contact information of controls and cases was
obtained from the health center’s TB clinic patient regis-
tration book. The selected individuals were contacted by
telephone and given information about the study. Indi-
viduals who were willing to participate and gave verbal
consent were scheduled for an interview at the health
facility.
Data collection
A structured questionnaire was used to collect informa-
tion from study participants. Secondary data were col-
lected from TB and MDR-TB registers. Patient charts
and the data collection format were used to determine
and record their initial TB episode. The FMOH screen-
ing tool was used to identify controls free of suspected
TB at the time of the study [7]. Day-long training was
provided to the nurses and health officers involved in
the data collection process. The main variables included
in study instrument were sex, age, socioeconomic status,
ethnicity, HIV status, adherence or non-adherence to the
first course of anti-TB treatment, number of previous
anti-TB treatments, treatment with the Category IIregimen, ever- interruption in taking medicine for a
day, and occurrence of drug side effects during the first
course of TB treatment.
Data management and analysis
Data were entered using Epidata version 3.1 and
exported to STATA version 11 for analysis. Data com-
pleteness and consistency were checked by running fre-
quencies of each variable. Bivariate analyses were carried
out for categorical variables, and odds ratios were used
to quantify the strength of association between potential
risk factors and MDR-TB. Multiple logistic regressions
were used to control the confounding effect of different
variables while assessing the effect of each variable on
the likelihood of MDR-TB occurrence. A p-value of 0.05
was used as the cut-off point for statistical significance.
Variables having a p-value of at most 0.05 in bivariate
analysis were included in the multivariate logistic regres-
sion model. In multivariate logistic regression, the ad-
justed effects of three variables (the number of
pulmonary TB episodes, ever-interruption in anti-TB
treatment for at least a day in the first course, and dur-
ation of the first course of TB treatment) were estimated
without concurrently adjusting for each other to avoid
multicollinearity.
Ethical considerations
Ethical clearance was obtained from the institutional re-
view board of the Aklilu Lemma Institute of Pathobiol-
ogy at Addis Ababa University and St. Peter Hospital.
Written permission to conduct the study was also
obtained from the managers of each health facility. A
statement about the purpose of the study was read to each
study participant, and those who gave verbal consent to
participate in the study were interviewed. Study partici-
pants were interviewed privately, and their names were
not written on the questionnaire to ensure confidentiality.
Results
Sociodemographic characteristics of study participants
A total of 134 cases and an equal number of controls
were included in the study. A total of 81 (60.5%) of the
MDR-TB cases were males, but females represented the
majority in the control group (70 females, or 52.5%).
Single or divorced individuals accounted for the majority
101 (75.3%) of the MDR-TB cases but only about half
(69, or 51.5%) in the control group (Table 1). The mean
age was 25.1 (SD = 10.94) years for MDR-TB cases and
30.72 (SD = 11.4) years for controls.
TB-related conditions
Table 2 summarizes TB-related conditions in the cases
and controls. Of the 134 MDR-TB cases, 96 (71.6%) had
had two or more episodes of TB treatment before they
Table 1 Sociodemographic characteristics of MDR-TB




(n = 134) (n = 134)
Number Percentage Number Percentage
Sex
Male 81 60.5 64 47.5
Female 53 39.5 70 52.5
Age at the time of first anti-TB treatment (years)
5–25 85 63.4 47 35.1
26–45 40 29.9 70 52.2
46–72 9 6.7 17 12.7
Marital status
Single 85 63.4 60 44.8
Married 32 23.8 56 41.8
Divorced 16 11.9 9 6.7
Widow/widower 1 0.75 9 6.7
Educational status
Up to fourth grade 15 11.2 25 18.6
Completed
5th –8th grade
16 11.9 20 15
Completed
8th –10th grade
27 20.1 25 18.6
Above 10th grade 76 56.7 64 47.8
Occupation
No work 31 23.1 31 23.1
Student 36 26.9 9 6.7
Daily laborer 2 1.5 13 9.7
Government worker 24 17.9 24 17.9
Private worker 31 23.1 42 31.3
Businessman 10 7.5 15 11.2
Number of rooms in residence
1 61 45.5 37 27.6
2–3 57 42.5 63 47
4–5 11 8.2 34 25.4
6–9 5 3.7 0 0
Family size
1–3 57 42.5 49 36.6
4–6 57 42.5 70 52.2
7–11 20 15 15 11.2
Table 2 Tuberculosis disease-related conditions in each
category (case/control) in Addis Ababa, 2011
Characteristics Cases Controls
(n = 134) (n = 134)
Number Percentage Number Percentage
No. of pulmonary TB episodes
One 29 21.6 119 88.8
Two 66 49.3 14 10.5
Three 30 22.4 0 0
Four or more 9 6.7 1 0.75
HIV status
Negative 116 86.6 94 70.2
Positive 18 13.4 40 29.9
Ever lived with MDR-TB patient
No 122 91.0 134 100
Yes 12 9.0 0 0
Site of TB infection during first episode
Pulmonary 130 97 90 67.2
Extrapulmonary 4 3.0 44 32.8
Smear-positive during first anti-TB treatment
No 11 8.2 82 61.2
Yes 123 91.8 52 38.8
Ever counseled by health worker
No 44 32.8 1 0.75
Yes 90 67.2 133 99.25
Presence of other disease
No 111 82.8 115 85.5
Yes 23 17.2 19 14.2
Ever smoked cigarettes
No 125 93.3 115 85.8
Yes 9 6.7 19 14.2
Perception about the care provided
Very good 5 3.7 87 64.9
Good 13 9.7 36 26.9
Satisfactory 77 55.5 8 6.0
Poor 39 29.1 3 2.2
Weight measured by health worker before starting treatment
No 3 2.2 0 0
Yes 120 89.6 134 100
Doesn’t remember 11 8.2 0 0
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had had four or more episodes of TB. In the control
group, only 14 (10.4%) had undergone two rounds of TB
treatment, and one case had suffered four or more epi-
sodes of TB. HIV positivity was significantly lower in the
MDR-TB cases than in the control group (13.4% versus
29.9%; p-value <0.001). The quality of care provided byhealth care providers was perceived as poor by 39 (29.1%)
of MDR-TB cases and by 3 (2.2%) of the controls.
Treatment-related conditions
Conditions related to anti-TB treatment are summarized
in Table 3. During first-line anti-TB treatment, drug side
Table 3 First-line tuberculosis treatment-related conditions
in MDR-TB cases and their controls in Addis Ababa, 2011
Characteristics Cases Controls
(n = 134) (n = 134)
Number Percentage Number Percentage
Encountered drug side effect
No 67 50.0 109 81.3
Yes 67 50.0 25 18.7
Suffered the most common drug side effect (vomiting)
No 85 63.4 124 92.5
Yes 49 36.6 10 7.5
Duration of first-time TB treatment
2–4 months 3 2.2% 1 0.75%
5–7 months 22 16.4% 2 1.5%
8 months 103 76.9% 128 95.5
9–13 months 6 4.5% 3 2.2%
Directly observed by health worker while taking anti-TB
No 65 48.5 7 5.2
Yes 69 51.5 127 94.8
If yes, how many months
1–2 weeks 11 15.95 0 0
One month 32 46.4 1 0.8
Two months 26 37.7 126 99.2
Reason for interruption for at least a day
Side effects 34 36.6 3 30.0
Forgot to take it 23 24.7 7 70.0
Symptoms were gone
and felt good
29 31.2 0 0
Shortage of drug 7 7.5 0 0
Ever interrupted anti-TB for at least a day
No 41 30.6 124 92.5
Yes 93 69.4 10 7.5
Took the medication at a regular time
No 81 60.5 25 18.7
Yes 53 39.5 109 81.3
Outcome of first anti-TB treatment
Treatment success 64 47.7 132 98.5
Defaulted 16 11.9 2 1.5
Treatment failure 54 40.3 0 0
Drug regimen (category) for the second time
Category II 101 94.4 3 23.1
Category I 6 5.6 10 76.9
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cases and 25 (18.7%) of the controls. Among the current
MDR-TB patients, their first-line anti-TB treatment was
directly observed by health workers in only 69 cases(51.5%), while 127 (94.8%) of the controls were treated
in accordance with the strict DOTS guidelines of the
country. First-line anti-TB treatment was interrupted for
at least a day in 93 (69.4%) of the MDR-TB cases, and in
only 10 (7.5%) of the controls. Out of the 16 MDR-TB
patients who were poor adherers of treatment in cat-
egory I treatment 10(62.5%) were male. Reasons for
interruption among MDR-TB cases were drug side ef-
fects in 34 cases (36.6%), followed by improved/dis-
appeared symptoms and the perception that TB was
cured 29 cases (31.2%), and forgetfulness about taking
the medicine 23 cases (24.7%). Duration of first-line
anti-TB treatment was exactly 8 months in 103 (76.9%)
of the MDR-TB cases and 128 (95.5%) of the controls.
Among the MDR-TB cases, the outcomes of the first
course of anti-TB treatment was reported as treatment
success in 64 cases (47.7%), defaulter in 16 cases
(11.9%), and treatment failure in 54 cases (40.3%). In the
controls, 132 (98.5%) were declared treatment successes.
Of the MDR-TB cases, 107 (79.9%), and 13 (9.7%) of the
controls, were treated at least twice with first-line anti-
TB treatment. Of the 107 current MDR-TB cases, 101
(94.4%) were also treated with the Category II regimen,
while only 3 (23.1%) of the 13 controls were treated with
the Category II regimen.
Results from logistic regression analysis
After adjusting for possible confounding factors (Table 4),
the study found that MDR-TB development is significantly
associated with two or more episodes of TB illness (AOR =
31.8; 95% CI; 8.7–115.5), interruption of first-line anti-TB
treatment for at least a day (AOR = 13.1; 95% CI; 3.0–
56.6), education above 10th grade (AOR = 3.7; 95% CI;
1.1–12.1), and male sex (AOR = 2.7; 95% CI; 1.1–6.5).
The number of rooms in the patient’s household also
showed a significant association with MDR-TB (AOR =
10.1; 95% CI; 2.0–49.4). Pulmonary TB (AOR = 10.9;
95% CI; 2.8–41.9), drug side effects during first-line
treatment (AOR = 4.5; 95% CI; 1.9–10.5), lack of direct
observation by health workers (AOR = 11.7; 95% CI;
4.0–34.3), and less than 7 months of first-line anti-TB
treatment (AOR= 14.8 95% CI; 2.3–96.4) were also signifi-
cantly associated with MDR-TB development. Fischer’s
exact test showed that being treated with the Category II
regimen was associated with MDR-TB development
(P = 0.000).
HIV status, history of smoking, experience of drug
shortages, and family size were not significantly associ-
ated with MDR-TB development.
Discussion
A case control study with equal number of cases and con-
trols was conducted by recruiting a total of 268 study par-
ticipants to determine factors associated with developing
Table 4 Determinants of multidrug-resistant tuberculosis
from logistic regression model
Characteristics Case Control Crude OR Adjusted OR
Number Number (95% CI) (95% CI)
Individually adjusted for the remaining variables
Number of pulmonary TB episodes
One 29 119 1 1
Two or more 105 15 28.7 (14.6-56.5) 31.8 (8.7-115.5)
Ever interrupted anti-TB for at least a day
No 41 124 1 1
Yes 93 10 28.1 (13.4-58.1) 13.1 (3.0-56.6)
Duration of first course of TB treatment (months)
2–7 25 3 10.0 (2.9-34.1) 14.8 (2.3-96.4)
≥8 109 131 1 1
Adjusted for all variables
Age when taking first-line anti-TB for the first time (years)
46–72 9 17 1 1
26–45 40 70 1.1 (0.4-2.6) 1.4 (0.3-5.8)
5–25 85 47 3.4 (1.4-8.3) 4.6 (1.1-20.5)
Marital status
Single 85 60 2.5 (1.4-4.3) 1.2 (0.5-3.3)
Married 32 56 1 1
Divorced/
separated




15 24 1 1
Completed
5th–8th grade
16 20 1.3 (0.5-3.2) 1.2 (0.3-5.1)
Completed
8th–10th grade
27 25 1.7 (0.7- 4.0) 1.4 (0.4-5.1)
Above 10th grade 76 64 1.9 (0.9-3.9) 3.7 (1.1-12.1)
Sex
Female 53 70 1 1
Male 81 64 1.7 (1.0-2.7) 2.7 (1.1-6.5)
Number of rooms in residence
4–9 16 34 1 1
2–3 57 63 1.9 (1.0-3.9) 3.3 (1.0-10.9)
1 61 37 3.5 (1.7-7.2) 10.1 (2.0-49.4)
Number of rooms in residence
4–9 16 34 1 1
2–3 57 63 1.9 (1.0-3.9) 3.3 (1.0-10.9)
1 61 37 3.5 (1.7-7.2) 10.1 (2.0-49.4)
Family size
1–3 57 49 1 1
4–6 57 70 0.7 (0.4-1.2) 1.6 (0.5-5.0)
7–11 20 15 1.2 (0.5-2.5) 2.9 (0.7-13.0)
Table 4 Determinants of multidrug-resistant tuberculosis
from logistic regression model (Continued)
HIV status
Negative 116 94 2.7 (1.5-5.1) 2.8 (0.9-8.5)
Positive 18 40 1 1
Site of TB infection during first episode
Extrapulmonary 4 44 1 1
Pulmonary 130 90 15.9 (5.5-45.8) 10.9 (2.8-41.9)
Encountered drug side effect
No 67 109 1 1
Yes 67 25 4.4 (2.5-7.6) 4.5 (1.9-10.5)
Encountered shortage of drug
No 106 124 1 1
Yes 28 10 3.3 (1.5-7.1) 2.7 (0.8-9.5)
Directly observed by health worker while taking anti-TB
Yes 69 127 1 1
No 65 7 17.1 (7.4-39.3) 11.7 (4.0-34.3)
Took the medication at a regular time
No 69 127 1 1
Yes 65 7 17.1 (7.4-39.3) 11.7 (4.0-34.3)
Ever smoked cigarettes
No 125 115 1 1
Yes 9 19 0.4 (0.19-1.0) 0.4 (0.1-1.8)
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which were associated with MDR-TB: the first site of TB
infection being pulmonary, encountering drug side effects
during the first course of treatment, having more than one
TB episode, undergoing the Category II regimen, and tak-
ing anti-TB treatment for less than 7 months.
The study also found that being male was a risk factor
for MDR-TB development. A study in Nigeria showed
that being male was a risk factor for defaulting from
anti-TB medication [14]. Similarly, this study showed
that among MDR-TB cases who were defaulters in their
first-line TB treatment, 62.5% were males. The associ-
ation between being male and having MDR-TB could be
due to the fact that males have a higher tendency not to
adhere to anti-TB treatment than females, thus increas-
ing their risk of developing MDR-TB. Another study
showed that individuals who do not take anti-TB medi-
cation regularly have increased risk for MDR-TB [15].
Our study also showed that individuals who did not take
first-line anti-TB drugs regularly had increased risk for
development of MDR-TB.
Evidence from a previous study has shown that poor
treatment adherence was a risk factor for MDR-TB [8].
The current study also showed that individuals who took
first-line anti-TB treatment for duration of 2 to 7 months
Hirpa et al. BMC Public Health 2013, 13:782 Page 7 of 9
http://www.biomedcentral.com/1471-2458/13/782had increased risk of developing MDR-TB. In Ethiopia,
the previous guideline for first-line anti-TB treatment
was 8 months’ duration, but the standard has been
changed to 6 months. TB therapy requires more than
90% adherence to facilitate cure [16], and 2 to 7 months
(25%–87.5% of the prescribed duration) is less than the
required duration to result in cure.
Additionally, individuals who were not under strict
DOTS per national guidelines during their first anti-TB
treatment had an 11.7 times increased risk for MDR-TB.
An analysis that used empirical data to determine the
impact of the expansion of the DOTS strategy on TB
case finding and treatment success found that countries
with full DOTS coverage had at least an 18% increase in
the treatment success rate [17]. An individual who is su-
pervised by a health worker is more likely to take the ap-
propriate dose of medicine and less likely to miss a
treatment. Furthermore, individuals who come for
DOTS have frequent contact with health workers and
thus have increased opportunities to get advice and
counseling, which might help them to adhere to medica-
tion protocol.
As expected, individuals who encountered drug side
effects during the first course of TB treatment had a 4.5
times increased risk of developing MDR-TB. Studies
done in three districts of Arsi Zone, Ethiopia, found that
anti-TB drug side effects were significantly associated
with a high rate of defaulting [18]. When patients de-
velop side effects, they tend to stop treatment, which fa-
vors the development of MDR-TB. If the DOTS strategy
of the nation were followed in all cases, there would be
a chance to counsel patients and even treat adverse drug
reactions before treatment interruption. In our study,
the first-line anti-TB treatment of 48.5% of the MDR-TB
cases was not directly observed. A systematic review of
29 published reports on risk factors associated with
MDR-TB in Europe revealed that previous treatment
was the strongest determinant of MDR-TB and that the
pooled risk of MDR-TB was 10.23 times higher in previ-
ously treated than in never-treated cases [19]. A study in
Uganda also showed that multiple TB episodes and
treatment failure were significantly associated with
MDR-TB [20]. Similarly, in Ethiopia, according to a na-
tionwide anti-TB drug resistance survey conducted in
2005, 1.6% of newly diagnosed TB cases were infected
with MDR-TB, while 11.8% of the MDR-TB cases were
previously treated TB cases [10].
One can see how MDR-TB is prevalent in individuals
who have a history of treatment compared to new pa-
tients. Similarly, the current study showed that having
more than one TB episode also increased risk for MDR-
TB. This may be related to the previous treatment out-
come, default, treatment failure, or relapse, or the patient
may have had MDR-TB initially.Having pulmonary TB during first anti-TB treatment
was associated with increased risk for MDR-TB. This
may also be associated with the fact that smear-positive
pulmonary TB individuals have a high bacterial load and
may not respond to the treatment within a short period
of time, as do those with a low bacterial load [21]. For
this reason, smear-positive pulmonary TB patients might
be more prone to develop MDR-TB. The other explan-
ation might be associated with diagnostic difficulties. In
case of extra pulmonary MDR- TB the bacterial load is
lower and difficult for definite diagnosis comparing to
pulmonary MDR-TB. Limited capacity of the existing la-
boratory facilities especially for the diagnosis of extra
pulmonary MDR-TB might explain the association of
being Pulmonary TB and having MDR-TB.
This study showed that individuals who were treated
by the Category II regimen had increased risk for MDR-
TB. More than one explanation may be given for the as-
sociation of Category II treatment and MDR-TB. These
individuals might have had a previous TB treatment his-
tory and registered for the treatment as treatment fail-
ures, defaulters, or relapse cases, or they might have
already had MDR-TB at the initiation of the Category II
regimen. Another explanation is that adding one drug in
the failing regimen could change susceptible strains and
lead to multidrug resistance. “Michael Iseman, the US-
based MDR-TB specialist, had 10 commandments for
the physicians not to change fully drug susceptible or-
ganisms to MDR-TB; the first one was never to add a
single drug to a failing regimen and the other nine were
to repeat the first commandment to make sure it was
well understood” [8]. WHO recommends that DST
should be done for all previously treated patients before
they are treated with the Category II drug regimen, and
in conditions where DST is not available, the Category II
regimen can be used for relapse, default, and treatment
failure for low- or medium-MDR-TB-burden countries
[9]. A cross-sectional study in South Africa showed that
retreatment patients had increased risk for any drug re-
sistance and MDR-TB [22]. Having a DST before
embarking on the Category II regimen is very important.
In Ethiopia, because of low laboratory capacity, per-
forming DST for all previously treated patients is difficult
even though the country is one of the high-MDR-TB- bur-
den countries. An individual’s treatment may fail because
they have already had MDR-TB or because drug resistance
was caused by the retreatment regimen [23]. This is be-
cause the patient has already taken all the drugs in the
Category II regimen in the previous treatment, except
streptomycin, which is the oldest drug.
In the current study, HIV status had no significant as-
sociation with MDR-TB. A study in Thailand showed
also that HIV status was not significantly associated with
MDR-TB [23]. In France, being HIV positive was
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ated with secondary MDR-TB [24]. A cross-sectional
study in South Africa showed that in retreated patients,
HIV had no significant association with MDR-TB [25].
The study participants in the current study were patients
who had a history of first-line anti-TB treatment. It is
possible that the result could have been different if all
study participants were primary MDR-TB cases rather
than MDR-TB cases who had a history of previous treat-
ment. A study in Ukraine showed that HIV-positive indi-
viduals had a 50% higher risk of developing MDR-TB at
their first TB infection [26]. This is because being HIV
positive is one risk factor for drug-susceptible TB, which
is related to immune system suppression. Being HIV
positive might carry the same risk of infection with
MDR-TB but may not contribute to the change of a
drug-susceptible strain of TB to MDR-TB.
The strengths of the current study are that study par-
ticipants in the control group finished first-line anti-TB
treatment two years before the study period, which re-
duced the chance of relapse. They were selected from
the five health facilities in Addis Ababa that reported the
most MDR-TB cases to St. Peter Hospital, so that cases
and controls would have a better likelihood of coming
from similar backgrounds and be most likely to receive
the same service. Regarding the case group, all cases that
fulfilled the eligibility criteria that were available during
the study period and willing to respond were included in
the study. This was helpful to decrease sampling error.
The current study is not without limitations, however.
Recall bias could be considered one potential challenge,
since some of the information was based on the recall of
the study participants. Furthermore, it was not clear
whether all cases had MDR-TB before or after undergo-
ing first-line TB treatment, since DST was not done be-
fore they took first-line TB treatment or Category II
regimens.
Conclusions
Non-adherence to the first line anti-TB treatment was
significantly associated with MDR-TB. Taking medica-
tion without interruption, taking medication regularly,
and having supervision (DOTS) had a protective effect
against MDR-TB. Having more than one pulmonary TB
episode had a significant association with MDR-TB. In-
dividuals who were treated with the Category II regimen
were also found to have an increased risk for MDR-TB.
HIV status was not significantly associated with MDR-
TB among individuals who had been previously treated
with first-line anti-TB drugs. Hence, strengthening
DOTS programs to enhance patient adherence to anti-
TB treatment and giving special attention to individuals
at high risk for MDR-TB and prioritizing them for DST
are recommended.Abbreviations
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